ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Obstetrics and Gynecology
ESPS manuscript NO: 18596
Title: Alpha1B adrenoceptor expression is a marker of reduced survival and increased tumor recurrence in patients with endometrioid ovarian cancer
Reviewer's code: 00742121
Reviewer's country: Greece
Science editor: Xue-Mei Gong
Date sent for review: 2015-04-29 12:15
Date reviewed: 2015-05-04 03:37

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[Y] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[Y] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

This is a well written paper worthy of publication after minor revision, according to the comments listed below. - Abstract:The "Objective" section should be shortened. -The term "cancer specific survival" used throughout the text should be probably replaced by "ovarian cancer specific survival". - There are some other terms used, that should be better changed (see comments in the manuscript). - The authors should discuss possible limitations of alpha adrenoreceptor antagonists in clinical practice, due to adverse effects of these agents.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Obstetrics and Gynecology
ESPS manuscript NO: 18596
Title: Alpha1B adrenoceptor expression is a marker of reduced survival and increased tumor recurrence in patients with endometrioid ovarian cancer
Reviewer's code: 00742253
Reviewer's country: Lithuania
Science editor: Xue-Mei Gong
Date sent for review: 2015-04-29 12:15
Date reviewed: 2015-05-14 21:57

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[Y] Accept
[Y] Grade B: Very good	[ ] Grade B: Minor language	[ ] The same title	[ ] High priority for
[ ] Grade C: Good	polishing	[ ] Duplicate publication	publication
[ ] Grade D: Fair	[ ] Grade C: A great deal of	[ ] Plagiarism	[ ] Rejection
[ ] Grade E: Poor	language polishing	[Y] No	[ ] Minor revision
	[ ] Grade D: Rejected	BPG Search:	[ ] Major revision
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

I would like to congratulate the Authors with this great work.   I am sure the readers will accept this paper with a big interest.   Would you please explain this sentence for me, thank you.   "Alpha1B adrenoceptor protein predicts increased risk of tumor recurrence and reduced mortality in patients with endometrioid type ovarian cancer."

ESPS PEER-REVIEW REPORT

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good		[ ] Duplicate publication	
[ ] Grade D: Fair	[ ] Grade C: A great deal of language polishing	[ ] Plagiarism	[ ] Rejection
[ ] Grade E: Poor		[Y] No	[ ] Minor revision
	[ ] Grade D: Rejected	BPG Search:	[Y] Major revision
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The manuscript titled "Alpha1b adrenoceptor expression is a marker of reduced survival and increased tumor recurrence in patients with endometrioid ovarian cancer" studied alpha-1B, alpha-2C, and beta-2 adrenoceptor in ovary cancer patients and analyzed their relationship with the patients mortality and recurrent of the cancer. Results have shown an association between expression of alpha-1B and patients survival as well as tumor recurrence in some specific type of ovary cancer. The authors concluded that alpha-1B adrenoceptor protein predicts the outcome of endometrioid type ovarian cancer. This manuscript choice a very important disease-ovary cancer and studied in the molecular biology level-adrenergic receptor expression. Patient number is appropriate, experimental methods are suitable. English is well written. Structure of the manuscript is good. Figures and tables are clear. Major concern: Normal expression or standard expression of adrenergic receptor is not included in the study nor related referenced discussed in the manuscript. We say high (up) expression or low (down) expression, usually is compare with the normal group or control group. Reviewer noticed the authors only compared between the ovary cancer groups. We know that tumor

type is usually associated with the outcomes and recurrence of the tumor. The author analyzed the expression of adrenergic receptor as present and absent and resulted in the p value in an overall of ovary cancer group. We don't know if the individual tumor type expression of adrenergic receptor is normal expression or abnormal expression. So, reviewer suggest add another group of adrenergic receptor expression from the ovary tissue without cancer. I believe the tissue may be obtained from previous patients with other disease. By this way, hopefully we could find out it is real up or down expression of the adrenergic receptors. As well in the mortality analysis, the study of a different group other than ovary cancer will demonstrate whether different expression of Alpha-1b is related with mortality just in ovary cancer patients or in patients other than ovary cancer.   Minor concerns: ? Some English spelling and grammar corrections. ? It is hard to understand figure 2 and figure 3. Suggest explain in more detail.